Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

Gamma-Hydroxybutyrate is a GABAB Receptor Agonist that Increases a Potassium Conductance in Rat Ventral Tegmental Dopamine Neurons

Theresa E. Madden and Steven W. Johnson
Journal of Pharmacology and Experimental Therapeutics October 1998, 287 (1) 261-265;
Theresa E. Madden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven W. Johnson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

γ-Hydroxybutyric acid (GHB) is an abused substance that occurs naturally in the basal ganglia. Electrophysiological recordings of membrane voltage and current were made to characterize the effects of GHB on dopamine neurons in the ventral tegmental area of the rat midbrain slice. Perfusate containing GHB caused a concentration-dependent membrane hyperpolarization (EC50 = 0.88 ± 0.21 mM) and a reduction in input resistance (EC50 = 0.74 ± 0.21 mM). The highest concentration of GHB studied (10 mM) hyperpolarized neurons by 20 ± 3 mV and reduced input resistance by 58% ± 9%. Changes in membrane potential and input resistance were blocked by the γ-aminobutyric acid antagonist CGP-35348 (300 μM), but neither bicuculline (30 μM) nor strychnine (10 μM) was an effective antagonist. Voltage-clamp recordings demonstrated that GHB (1 mM) evoked 80 ± 6 pA of outward current (at −60 mV) that reversed at −110 mV (in 2.5 mM K+). Increasing concentrations of extracellular K+ progressively shifted the reversal to more depolarized potentials. In tetrodotoxin (0.3 μM) and tetraethylammonium (10 mM), depolarizing voltage steps (to −30 mV) evoked calcium-dependent current spikes that were completely blocked by GHB (1 mM). These data suggest that GHB is an agonist at γ-aminobutyric acid receptors and would be expected to inhibit DA release by causing K+-dependent membrane hyperpolarization.

Footnotes

  • Send reprint requests to: Steven W. Johnson, M.D., Ph.D., Department of Physiology & Pharmacology, L-334, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon 97201.

  • ↵1 This work was supported by USPHS grants MH40416 and DA07262.

  • Abbreviations:
    aCSF
    artificial cerebrospinal fluid
    BMI
    bicuculline methiodide
    DA
    dopamine
    Erev
    reversal potential
    GABA
    γ-aminobutyric acid
    GHB
    γ-hydroxybutyric acid
    SN
    substantia nigra
    TEA
    tetraethylammonium
    TTX
    tetrodotoxin
    VTA
    ventral tegmental area
    • Received November 12, 1997.
    • Accepted May 22, 1998.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 287, Issue 1
1 Oct 1998
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Gamma-Hydroxybutyrate is a GABAB Receptor Agonist that Increases a Potassium Conductance in Rat Ventral Tegmental Dopamine Neurons
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Gamma-Hydroxybutyrate is a GABAB Receptor Agonist that Increases a Potassium Conductance in Rat Ventral Tegmental Dopamine Neurons

Theresa E. Madden and Steven W. Johnson
Journal of Pharmacology and Experimental Therapeutics October 1, 1998, 287 (1) 261-265;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Gamma-Hydroxybutyrate is a GABAB Receptor Agonist that Increases a Potassium Conductance in Rat Ventral Tegmental Dopamine Neurons

Theresa E. Madden and Steven W. Johnson
Journal of Pharmacology and Experimental Therapeutics October 1, 1998, 287 (1) 261-265;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • PST3093 Stimulates SERCA2a and Improves Cardiac Function
  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Antagonist-Induced Reversal of Functional and Structural Measures of Hippocampal Benzodiazepine Tolerance
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics